Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 21, 2009 9:31 AM

Published 11/07/2009 by GenomeWeb


Everything you wanted to know about GPUs but were afraid to ask

If, like an elderly person listening to the din of grandchildren rambling on about something called 'texting,' you're feeling left out of all this GPU hubbub, the National Center for Supercomputing Applications (NCSA) at the University of Illinois may be able to help. The...

Share this 

There are no more reports on this story yet.

Related Stories

First Reported 11/02/2009 - Updated 11/02/2009 - 5 Documents (in Health)
Food and Drug Administration - Click to view 360-page
Food and Drug Administration
Lupus drug completes testing, heads to FDA for approval
Rockville-based Human Genome Sciences Inc. announced on Monday that its experimental Lupus drug has completed its final round of testing at a higher dose and will now be headed to the Food and Drug Administration for approval.The latest round of studies ... [Washington Post - 11/02/2009]
In Focus
Network

Blogs

sort by: Date | Relevance
Could We Be On the Verge of a New Drug to Treat... [Scientific American - Observations - 11/03/2009]
Systemic lupus is the most common form of the autoimmune disease, lupus , which afflicts about 5 million people worldwide and causes a slew of symptoms including ...
Innovative Drug Companies Headline the Gainers [Healthcare Sector and Stocks Analysis from Seek ... - 11/02/2009]
Ockham Research submits: For all the debate about possible reform to the U.S. medical system, it is easy to forget that the majority of major innovations in drugs ...
Innovative Drug Companies Headline the Gainers [Long Investment Ideas from Seeking Alpha - 11/02/2009]
Ockham Research submits: For all the debate about possible reform to the U.S. medical system, it is easy to forget that the majority of major innovations in drugs ...
Trial Results Bode Well for Human Genome Sciences [Healthcare Sector and Stocks Analysis from Seek ... - 11/02/2009]
EP Vantage submits:The high hopes that both the market and sufferers from lupus hold for Human Genome Sciences' (HGSI) lead drug, Benlysta, showed no signs of being ...
Lower Third Quarter Loss for Human Genome [Healthcare Sector and Stocks Analysis from Seek ... - 11/05/2009]
Zacks.com submits: Human Genome Sciences, Inc. (HGSI) reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. ...
1 2

Audio/Video

sort by: Date | Relevance
Watkins Says Benlysta Could Be Available by End... [Bloomberg - YouTube - 11/02/2009]
1

  •  
  •  
  •